Orthopaedic management improves the rate of early osteoporosis treatment after hip fracture a randomized clinical trial

Journal of Bone and Joint Surgery

Volumn 90, Issue 11, 2008, Pages 2346-2353

  Miki, Roberto A ^a   Oetgen, Matthew E ^b   Kirk, Jessica ^b   Insogna, Karl L ^b   Lindskog, Dieter M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; HIP FRACTURE; HUMAN; LABORATORY TEST; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 55849131362     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.G.01246     Document Type: Article

References (40)

1. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767-78.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.
3. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR; Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-24. Erratum in: J Clin Endocrinol Metab. 2001;86:938.
4. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809.
5. Hooven F, Gehlbach SH, Pekow P, Bertone E, Benjamin E. Follow-up treatment for osteoporosis after fracture. Osteoporos Int. 2005;16:296-301.
6. Andrade SE, Majumdar SR, Chan KA, Buist SM, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163:2052-7.
7. Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis. 1998;57:378-9.
8. Gardner MJ, Flik KR, Mooar P, Lane JM. Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am. 2002;84:1342-8.
9. Orwig DL, Wehren L, YuYahiro J, Hochberg M, Magaziner J. Treatment of osteoporosis following a hip fracture: sending results of bone densitometry to primary care physicians does not increase use of pharmacologic therapy. J Bone Min Res. 2001;15:S220.
10. Streeten EA, Mohamed A, Gandhi A, Orwig D, Sack P, Sterling R, Pellegrini VD Jr. The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed? J Bone Joint Surg Am. 2006;88:1968-74.
11. Gardner MJ, Brophy RH, Demetrakopoulos D, Koob J, Hong R, Rana A, Lin JT, Lane JM. Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Joint Surg Am. 2005;87:3-7.
12. Bahl S, Coates PS, Greenspan SL. The management of osteoporosis following hip fracture: have we improved our care? Osteoporos Int. 2003;14:884-8.
13. Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am. 2003;85:2294-302.
14. Follin SL, Black JN, McDermott MT. Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy. 2003;23:190-8.
15. Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum. 2002;47:651-4.
16. Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000;82:1063-70.
17. Kamel HK, Hussain MS, Tariq S, Perry HM, Morley JE. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med. 2000;109:326-8.
18. Hawker G, Ridout R, Ricupero M, Jaglal S, Bogoch E. The impact of a simple fracture clinic intervention in improving the diagnosis and treatment of osteoporosis in fragility fracture patients. Osteoporos Int. 2003;14:171-8.
19. McLellan AR, Gallacher SJ, Fraser M, McQuillian C. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int. 2003;14:1028-34.
20. Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:16-23.
21. Kaufman JD, Bolander ME, Bunta AD, Edwards BJ, Fitzpatrick LA, Simonelli C. Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg Am. 2003;85:1837-42.
22. Bogoch ER, Elliot-Gibson V, Beaton DE, Jamal SA, Josse RG, Murray TM. Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am. 2006;88:25-34.
23. Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77:334-8.
24. Skedros JG, Holyoak JD, Pitts TC. Knowledge and opinions of orthopaedic surgeons concerning medical evaluation and treatment of patients with osteoporotic fracture. J Bone Joint Surg Am. 2006;88:18-24.
25. Jaglal SB, McIsaac WJ, Hawker G, Carroll J, Jaakkimainen L, Cadarette SM, Cameron C, Davis D. Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process. Osteoporos Int. 2003;14:672-6.
26. Taylor JC, Sterkel B, Utley M, Shipley M, Newman S, Horton M, Fitz-Clarence H. Opinions and experiences in general practice on osteoporosis prevention, diagnosis and management. Osteoporos Int. 2001;12:844-8.
27. Che M, Ettinger B, Liang J, Pressman AR, Johnston J. Outcomes of a disease-management program for patients with recent osteoporotic fracture. Osteoporos Int. 2006;17:847-54.
28. Cuddihy MT, Amadio PC, Melton LJ 3rd. Patient barriers to osteoporosis interventions after fracture. Mayo Clinic Proc. 2002;77:875-6.
29. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Your Medicare Benefits. http://www.medicare.gov/Publications/ Pubs/pdf/10116.pdf. Accessed 2008 July 6.
30. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22.
31. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589-95.
32. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol. 2004;43:2036-43.
33. Colon-Emeric CS, Sloane R, Hawkes WG, Magaziner J, Zimmerman SI, Pieper CF, Lyles KW. The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture. Am J Med. 2000;109:324-6.
34. Schroder HM, Petersen KK, Erlandsen M. Occurrence and incidence of the second hip fracture. Clin Orthop Relat Res. 1993;289:166-9.
35. Lawrence TM, Wenn R, White C, Moran CG. The second hip fracture: risk factors and incidence. Read at the Annual Meeting of the Orthopaedic Trauma Association; 2003 Oct 9-11; Salt Lake City, UT.
36. Melton L J 3rd, Ilstrup DM, Beckenbaugh RD, Riggs BL. Hip fracture recurrence. A population-based study. Clin Orthop Relat Res. 1982;167:131-8.
37. Fox KM, Magaziner J, Hawkes WG, Yu-Yahiro J, Hebel JR, Zimmerman SI, Holder L, Michael R. Loss of bone density and lean body mass after hip fracture. Osteoporos Int. 2000;11:31-5.
38. Dirschl DR, Piedrahita L, Henderson RC. Bone mineral density 6 years after a hip fracture: a prospective, longitudinal study. Bone. 2000;26:95-8.
39. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129-35.
40. Riggs BL, Melton L J 3rd. The prevention and treatment of osteoporosis. N Engl J Med. 1992;327:620-7.